Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Ervebo (V920) Ebola Vaccine in Healthy Adults
NCT02314923Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2014
- Primary completion
- Jun 2016
- Modality
- Viral Vector Vaccines
01
Overview
Phase 1, randomised, double-blind trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (10 cohorts), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity at 14 days, Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity at 14 days and 4 more. Started Dec 2014; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02314923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314923.